Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease

NCT05698901 | Recruiting FDA Drug

• 1 other identifier: 22CT026be
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by deficient activity of the enzyme α-Gal A resulting from mutations affecting the GLA gene. It is characterized by severe multi-systemic involvement that leads to major organ failure and premature death in affected men and in some women. The α-Gal A deficiency results in progressive accumulation of un-degraded glycosphingolipids, predominantly globotriaosylceramide (Gb3), within cell lysosomes throughout the body.1 In patients at the fourth to fifth decade, left ventricular hypertrophy occur usually, and myocardial infarction and heart failure develops disease progress. Life-threatening renal, cardiac, and cerebrovascular diseases are added in later decades.2,3 Fabry disease is treatable with enzyme replacement therapy (ERT). Early recognition of symptoms and diagnosis of patients at a potentially reversible stage of the disease is therefore important. To date, plasma Lyso-Gb3 is useful in the diagnosis of Fabry disease. All male with classical Fabry disease could be discerned by an elevated plasma Lyso-GL-3; All adult female patients have elevated plasma Lyso-GL-3 above normal range.4 Other study also indicated that higher lyso-Gb3 concentrations at first visit were associated with a higher event rate in the past. Men with classical FD have higher Lyso-GL-3 values compared with patients with non-classical FD and women along with an increased risk of developing complications, more severe cardiac and renal disease.5 According to a publication from Taiwan society of cariology (TSOC) expert consensus, several cardiac biomarkers including N terminal pro B type natriuretic peptide (NT-proBNP) and cardiac troponin I/T (cTNI/cTNT) have been proposed to be alternative surrogate markers of cardiac involvement in FD.6However, there is no study to analyze the relationship between all these biomarkers including lyso-Gb3 and FD cardiac manifestation or improvement of cardiac damage outcomes under ERT yet. There is a high prevalence of the cardiac variant (IVS4+919G→A) (\~1 in 1600 males) of FD in Taiwan as revealed by newborn screening programs7,8 and patients with idiopathic HCM.9 FD patients with cardiac variant need to fulfill at least two indicators as stated in "cardiac function assessment indicators of Fabry's disease cardiac variant type" with cardiac biopsy confirmed GL3 or lyso-Gb3 lipid accumulation to get local reimbursement for treatment. Cardiac biopsy is an invasive and relative dangerous procedure that some patients would refuse to take this procedure and could not get local reimbursement resulting in delay in treatment. Therefore in the present study the investigators are aiming to identify candidate biomarkers to establish a scoring algorithm for evaluating Fabry disease progression status or treatment response and the investigators could stage patient who with more correlated biomarkers at baseline would have higher risk to develop sever clinical outcome and initiate early therapy.

Conditions

Fabry Disease

Keywords

Fabry Disease; Disease progression; Cardiac biomarkers; Therapy response

Outcome Measures

Primary Outcomes (1)

• To establish a comprehensive scoring algorithm to evaluate the disease progression status and potential indicators in response to treatment outcome mainly from imaging or biomarkers.

  3 years

Secondary Outcomes (2)

• (a)To figure out which biomarker and imaging data is statistically significant associated with disease progression status in patients without treatment.

  3 years

• To further analyze and confirm from (a) that treatment outcomes (biomarkers/imaging parameters) of patient exposed to agalsidase beta therapy were statistically significant.

  3 years

Study Arms (2)

Group A

1. 18 years or older 2. Male or female with Fabry disease diagnosed 3. Presence of any one of following abnormal criteria of either: 1) Cardio-specific Biomarker; 2) Abnormal elevated value of plasma Gb3 or Lyso-Gb3; 3) Electrocardiography (ECG); 4) Cardio-specific Image. 4. ERT Treatment naïve Fabry patients

Group B

1. 18 years or older 2. Male or female with Fabry disease diagnosed 3. Presence of any one of following abnormal criteria of either: 1) Cardio-specific Biomarker; 2) Abnormal elevated value of plasma Gb3 or Lyso-Gb3; 3) Electrocardiography (ECG); 4) Cardio-specific Image. 4. Agalsidase beta (ERT) exposed or treated Fabry patients

Drug: Agalsidase beta

Interventions

Agalsidase beta DRUG

The treatment is following local reimbursement criteria and judge by physician

Group B

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Diagnosed FD patients with cardiac manifestation will be included and classified into two group based on their treatment status: treatment naïve or treated. Treatment naïve patient will be assigned to group A; Treated patient will be assigned to group B. If patient from group A meet the treatment criteria and about to have ERT, he/she could be re-assigned to group B.

You may qualify if:

• years or older
• Male or female with Fabry disease diagnosed
• Presence of any one of following abnormal criteria of either: 1) Cardio-specific Biomarker; 2) Abnormal elevated value of plasma Gb3 or Lyso-Gb3; 3) Electrocardiography (ECG); 4) Cardio-specific Image.
• Group A: ERT Treatment naïve Fabry patients
• Group B: Agalsidase beta (ERT) exposed or treated Fabry patients
• Willing and able to comply with the required clinic visits, study procedures and assessments

You may not qualify if:

• Patient who are unwilling to sign inform consent form

Sponsors & Collaborators

• Mackay Memorial Hospital: lead

Study Sites (1)

Charles Jia-Yin Hou

Taipei, Taiwan

RECRUITING

MeSH Terms

Conditions

Fabry Disease; Disease Progression

Interventions

agalsidase beta

Condition Hierarchy (Ancestors)

Sphingolipidoses; Lysosomal Storage Diseases, Nervous System; Brain Diseases, Metabolic, Inborn; Brain Diseases, Metabolic; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Cerebral Small Vessel Diseases; Cerebrovascular Disorders; Vascular Diseases; Cardiovascular Diseases; Genetic Diseases, X-Linked; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Metabolism, Inborn Errors; Lipidoses; Lipid Metabolism, Inborn Errors; Lysosomal Storage Diseases; Metabolic Diseases; Nutritional and Metabolic Diseases; Lipid Metabolism Disorders; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Charles Jia-Yin Hou

  Mackay Memorial Hospital

  STUDY CHAIR

Central Study Contacts

Charles Jia-Yin Hou

CONTACT

+886905960500; jiayinhou@gmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: January 16, 2023
• First Posted: January 26, 2023
• Study Start: September 19, 2023
• Primary Completion (Estimated): September 30, 2026
• Study Completion (Estimated): September 30, 2027
• Last Updated: November 18, 2023

Record last verified: 2023-11

Locations

TW (1)